Press release – MIB and MImAbs partner to accelerate antibody discovery

Marseille, 3 november 2026 – MIB and MImAbs SAS, a Janvier Biosciences group company, announce a partnership in antibody discovery.

MIB is a French immunology biocluster specialising in the early stages of immunotherapy development, particularly for autoimmune and infectious diseases, and in the discovery of new immunotherapies, including antibodies, recombinant proteins and innovative cell therapies.

MImAbs discovers antibodies from immunised animals and develops them in various formats, including bispecific antibodies and antibody-drug conjugates (ADCs).

Both partners use the Beacon® platform, a single B-cell screening technology that directly analyses thousands of antibody-producing cells in parallel. This enables candidates of interest to be identified within days.

Two independent platforms with complementary expertise

MIB – B-Screen platform

Discovery and characterisation of human antibodies from patient samples. B-Screen provides rapid access to naturally produced antibodies in different disease settings and helps to improve understanding of the associated immune responses.

MImAbs – MIMA-SCREEN platform

Rapid discovery of antibodies from the repertoires of immunised animals, including mice, rabbits and llamas, using immunisation strategies optimised for each target, including the most challenging. MIMA-SCREEN selects candidates based on their functional properties. MImAbs then integrates these candidates into its engineering and preclinical evaluation pipeline, progressing to in vivo efficacy studies.


A partnership to support projects

MIB and MImAbs will share their expertise in using Beacon® and may combine their approaches for projects where this is appropriate. For scientific and clinical teams, academic groups, biotech companies and pharmaceutical companies, this means access in Marseille to expertise suited to their needs and to technology that significantly shortens discovery timelines, with the freedom to work with either or both partners.

“Patients are at the heart of our approach. Bringing together our expertise in human immune repertoires and MImAbs’ expertise in therapeutic antibody discovery within the Marseille ecosystem creates another bridge between clinical care and innovation.”

“ With Beacon ®, we can identify candidates in a few days that previously took months of work to find. Partnering with MIB allows us to combine our antibody discovery and engineering capabilities with recognised clinical expertise, for the benefit of the biotech and pharmaceutical companies that place their trust in us.”

About MIB

Marseille Immunology Biocluster (MIB) brings together founding members from research, healthcare and industry. Supported by €96 million in funding under France 2030, the project develops technology platforms and supports innovation in immunology, particularly in oncology, infectious diseases, and autoimmune and inflammatory diseases.

About MImAbs

MImAbs, a Janvier Biosciences group company, is a contract research organisation (CRO) specialising in the discovery, engineering and preclinical development of therapeutic antibodies. It supports research institutes, biotech companies and the pharmaceutical industry with a tailored approach, from immunisation through to efficacy studies

Actualités

Les dernières
actualités